Head & Neck Cancer

June 5th 2024

Phase 2 data may support petosemtamab as a best-in-class treatment for frontline HNSCC, according to Jérôme Fayette, MD.

May 8th 2024

Phase 2 data also highlight an improvement in disease control rate with setanaxib/pembrolizumab in squamous cell carcinoma of the head and neck.

April 28th 2024

Nurses must increase the frequency of their assessments for early intervention of patients who undergo treatment for their head and neck cancer, in an effort to truly individualized care.

April 12th 2024

LYT-200 is currently being investigated for those with solid tumors and hematologic malignancies.